Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- February 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 3
- GSK Investigational Site · Maitland, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Stuart, FL
New Jersey · 1
- GSK Investigational Site · Toms River, NJ
New York · 1
- GSK Investigational Site · Staten Island, NY
North Carolina · 1
- GSK Investigational Site · Matthews, NC
Oklahoma · 1
- GSK Investigational Site · Oklahoma City, OK
Texas · 1
- GSK Investigational Site · Houston, TX
Virginia · 1
- GSK Investigational Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.